Erratum: A model-based approach to dose selection in early pediatric development (Clinical Pharmacology and Therapeutics (2010) 87 294-302 doi:10.1038/clpt.2009.234);A model-based approach to dose selection in early pediatric development

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 3, 2010, Pages 294-302

  Cella, M ^a   De Vries, F Gorter ^a   Burger, D ^b   Danhof, M ^a   Pasqua, O Della ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY WEIGHT; CHILD; CHILD DEVELOPMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 77149131529     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.38     Document Type: Erratum

References (27)

1. Anderson, B.J. & Holford, N.H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303-332 (2008).
2. Caldwell, P.H., Murphy, S.B., Butow, P.N. & Craig, J.C. Clinical trials in children. Lancet 364, 803-811 (2004).
3. Della Pasqua, O., Zimmerhackl, L.B. & Rose, K. Study and protocol design for paediatric patients of diferent ages. In Guide to Paediatric Clinical Research (eds. Rose, K. & Van den anker, J.N.) 87-107 (Karger, Basel, 2007).
4. Simmons, P. abacavir sulfate (Ziagen). Res. Initiat. Treat. Action 5, 8-10 (1999).
5. Jullien, V. et al. Weight related diferences in the pharmacokinetics of abacavir in hIV-infected patients. Br. J. Clin. Pharmacol. 59, 183-188 (2005).
6. Jullien, V. et al. abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis. J. Clin. Pharmacol. 45, 257-264 (2005).
7. Ziagen [product information]. GlaxoSmithKline, Research Triangle Park, Nc 2008.
8. European Medicines agency. Ich Topic E11: Clinical Investigation of Medicinal Products in the Paediatric Population. cPMP/Ich/2711/99 (2001).
9. Waters, L. & Moyle, G. abacavir/lamividune combination in the treatment of hIV-1 infection: a review. Expert Opin. Pharmacother. 7, 2571-2580 (2006).
10. European Medicines agency. EPaR for authorised Medicinal Products for human Use: Ziagen (2009). accessed 19 May 2009.
11. Thomson, A.H. & Whiting, B. Bayesian parameter estimation and population pharmacokinetics. Clin. Pharmacokinet. 22, 447-467 (1992).
12. Chittick, G.E. et al. abacavir: absolute bioavailability, bioequivalence of three oral formulations, and efect of food. Pharmacotherapy 19, 932-942 (1999).
13. Weller, S., Radomski, K.M., Lou, Y. & Stein, D.S. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 44, 2052-2060 (2000).
14. A study to compare the pharmacokinetics of, and tolerability to, a single, oral, 600 mg dose of 1592U89 in hIV positive subjects with and without liver disease. Study No. aPV cNaB1006 (Clinical Study Protocol, GlaxoWellcome, 2000)
15. A study to determine the absolute bioavailability of an oral tablet formulation of 1592U89 in hIV-1 infected subjects (Clinical Study Protocol, GlaxoWellcome, 1998).
16. A study to assess the bioequivalence of the 300 mg 1592U89 hemisulfate tablet and the 100 mg 1592U89 succinate caplet, the efect of food upon bioavailability of the 300 mg tablet and the bioavailability of the 300 mg tablet relative to the new oral 1592U89 hemisulfate solution in hIV-1 infected subjects (Clinical Study Protocol, GlaxoWellcome, 1998)
17. A study to investigate whether there is a pharmacokinetic interaction between 1592U89 and ethanol following their co-administration to hIV-infected subjects (Clinical Study Protocol, GlaxoWellcome, 1998)
18. A study to evaluate the single dose and steady state pharmacokinetics/ dynamics of 1592U89 and its active moiety, 1144U88 5'-triphosphate, following six diferent dosing regimens of 1592U89 in hIV-1 infected subjects (Clinical Study Protocol, GlaxoWellcome, 2000)
19. A phase II study to evaluate the safety and Efficacy of diferent regimens of 1592U89 monotherapy upon selected immunological and virological markers of hIV-1 infection in antiretroviral therapy naïve patients (Clinical Study Protocol, GlaxoWellcome, 1998).
20. Bergshoef, A. et al.; PENTa-13 Study Group. Plasma pharmacokinetics of once-versus twice-daily lamivudine and abacavir: simplification of combination treatment in hIV-1-infected children (PENTa-13). Antivir. Ther. (Lond.) 10, 239-246 (2005).
21. Boeckman, A., Sheiner, A. & Beal, S. NONMEM VI (GloboMax, IcON Development Solutions, Ellicott city, MD, 2007).
22. Hooker, A.C., Staatz, C.E. & Karlsson, M.O. Conditional weighted residuals (cWRES): a model diagnostic for the FOcE method. Pharm. Res. 24, 2187-2197 (2007).
23. Frame, B. Mixture modeling with NONMEM V. In Pharmacometrics: The Science of Quantitative Pharmacology (eds. Ette, E.I. & Williams, P.J.) 723-757 (Wiley, New York, 2007).
24. Gisleskog, P.O., Karlsson, M.O. & Beal, S.L. Use of prior information to stabilize a population data analysis. J. Pharmacokinet. Pharmacodyn. 29, 473-505 (2002).
25. Langdon, G., Gueorguieva, I., Aarons, L. & Karlsson, M. Linking preClinical and Clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM. Eur. J. Clin. Pharmacol. 63, 485-498 (2007).
26. Lindbom, L., Ribbing, J. & Jonsson, E.N. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75, 85-94 (2004).
27. Hughes, W. et al. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob. Agents Chemother. 43, 609-615 (1999).